Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...

"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m. ET and was down as ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Dr Jack Mosley researched GLP-1 drug brands including Ozempic with his father and has written the book Food Noise.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Margaret has been described as someone who "touched the hearts and changed the lives of millions of people". | ITV News ...

An 18-year-old girl from Thalassery suffering from the eating disorder 'Anorexia' died at Thalassery co-operative hospital ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on ...

DEAR ABBY: My wife and I went for our annual checkups seven months ago. We were both overweight and told by our respective ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...